dc.contributor.author | Molina-Ortega, A | |
dc.contributor.author | Martín-Gandul, C | |
dc.contributor.author | Mena-Romo, J D | |
dc.contributor.author | Rodríguez-Hernández, M J | |
dc.contributor.author | Suñer, M | |
dc.contributor.author | Bernal, C | |
dc.contributor.author | Sánchez, M | |
dc.contributor.author | Sánchez-Céspedes, J | |
dc.contributor.author | Perez-Romero, Pilar | |
dc.contributor.author | Cordero, E | |
dc.date.accessioned | 2020-06-04T10:03:55Z | |
dc.date.available | 2020-06-04T10:03:55Z | |
dc.date.issued | 2019-06 | |
dc.identifier.citation | Clin Microbiol Infect. 2019 Jun;25(6):753-758. | es_ES |
dc.identifier.issn | 1198-743X | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/10272 | |
dc.description.abstract | INTRODUCTION: Although solid organ transplant (SOT) recipients with pretransplant serology for cytomegalovirus (CMV-R+) are considered at intermediate risk for CMV infection post transplantation, CMV infection remains a major cause of morbidity in this population. We prospectively characterized whether having pretransplant CMV-specific cellular immunity is independently associated with controlling infection after transplantation in R + SOT recipients. METHODS: A prospective cohort of consecutive R + SOT recipients that received pre-emptive treatment for CMV infection was monitored after transplantation and variables were recorded during the follow-up. The cytomegalovirus-specific T-cell immune response was characterized by intracellular cytokine staining and viral loads determined using real-time PCR. RESULTS: One hundred and thirty-five R + SOT recipients were included (67 kidney, 64 liver, four liver-kidney). Only one-third of the patients (42; 31.85%) had CMV-specific T-cell immunity (CD8+CD69+INF-γ+ T cells >0.25%) before transplantation. Patients with negative pretransplant immunity had more CMV infection (49, 52.7% vs. 15, 35.7%; p 0.07) and received more antiviral therapy than those with immunity (32, 34.4% vs. 6, 14.3%, p 0.016). Having CMV specific immunity was an independent factor for protection from developing viraemia ≥2000 IU/mL (OR 0.276, 95% CI 0.105-0.725, p < 0.01) and lower administration of treatment (OR 0.398, 95% CI 0.175-0.905, p 0.028). Only patients with no pretransplant CMV-specific T-cell response were diagnosed with CMV-disease (8, 8.6% vs. 0, 0%, p 0.05). DISCUSSION: Our results show that having a pretransplant CMV specific T-cell response may be associated with a lower rate of CMV viraemia and less antiviral treatment after transplantation; however, more prospective studies are needed to confirm these findings. | es_ES |
dc.description.sponsorship | This study was funded by from the Instituto de Salud Carlos III (grant number: PI11-02800; PI11-01357; PI14-00165), and – co-financed by European Development Regional Fund “A way to achieve Europe” ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015/0001). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.type.hasVersion | AM | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | CMV | es_ES |
dc.subject | CMV-specific immune response | es_ES |
dc.subject | Cytomegalovirus infection | es_ES |
dc.subject | Replication episodes | es_ES |
dc.subject | Serological status | es_ES |
dc.subject | Solid organ transplantation | es_ES |
dc.subject.mesh | Adolescent | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Aged | es_ES |
dc.subject.mesh | Cytokines | es_ES |
dc.subject.mesh | Cytomegalovirus | es_ES |
dc.subject.mesh | Cytomegalovirus Infections | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Organ Transplantation | es_ES |
dc.subject.mesh | Prospective Studies | es_ES |
dc.subject.mesh | Staining and Labeling | es_ES |
dc.subject.mesh | T-Lymphocytes | es_ES |
dc.subject.mesh | Viral Load | es_ES |
dc.subject.mesh | Young Adult | es_ES |
dc.title | Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 30292792 | es_ES |
dc.format.volume | 25 | es_ES |
dc.format.number | 6 | es_ES |
dc.format.page | 753-758 | es_ES |
dc.identifier.doi | 10.1016/j.cmi.2018.09.019 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.contributor.funder | RETICS-Investigación en Patología Infecciosa (REIPI-ISCIII) (España) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1469-0691 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.cmi.2018.09.019 | es_ES |
dc.identifier.journal | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/PI11-01357 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/RD12/0015/0001 | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2011) (2011)/PI11/02800 | |
dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2014). Modalidad proyectos en salud. (2014)/PI14/00165 | |